This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Kyungpook National University Industry-Academic Cooperation Foundation. Active years: 2022.
Company Filing History:
Years Active: 2022
Title: Smriti Gurung: Innovator in Cancer Immunotherapy
Introduction
Smriti Gurung is a notable inventor based in Daegu, South Korea. She has made significant contributions to the field of cancer immunotherapy through her innovative research and development of peptides that target PD-L1, a protein involved in immune response regulation.
Latest Patents
Gurung holds a patent for a peptide bound to PD-L1 and its applications in cancer immunotherapy. The invention focuses on two specific peptides, PD-L1Pep-1 and PD-L1Pep-2, which effectively bind to cells with high expression of the human PD-L1 protein. This binding inhibits PD-L1's function, thereby activating immune cells against cancer cells and demonstrating anticancer effects. The peptides have shown stability in blood and comparable efficacy to antibodies, indicating their potential as future cancer immunotherapy agents.
Career Highlights
Smriti Gurung is affiliated with the Kyungpook National University Industry-Academic Cooperation Foundation, where she continues her research and development efforts. Her work is characterized by a commitment to advancing cancer treatment options through innovative peptide technology.
Collaborations
Gurung collaborates with Byung-Heon Lee, contributing to the advancement of their shared research goals in cancer immunotherapy.
Conclusion
Smriti Gurung's innovative work in developing PD-L1 targeting peptides represents a significant advancement in cancer immunotherapy. Her contributions have the potential to improve treatment outcomes for cancer patients in the future.